-
Publication Venue For
-
Associations between complete remission and 2- to 3-year survival following 7 + 3 induction for acute myeloid leukemia..
1-6.
2021
-
Hepatitis B virus antibody status provides new insights in diffuse large B-Cell lymphoma..
1-4.
2021
-
Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma..
62:598-605.
2021
-
Targeting the glucagon receptor signaling pathway as a novel strategy to counteract PI3K inhibitor induced hyperglycemia while sustaining tumor PI3K inhibition..
1-6.
2021
-
Predicting severe toxicities with intensive induction chemotherapy for adult acute myeloid leukemia: analysis of SWOG Cancer Research Network trials S0106 and S1203..
1-7.
2021
-
Improving end-of-life care for patients with leukemia: is inpatient death the right measure?.
61:2546-2548.
2020
-
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes..
60:3161-3171.
2019
-
Experts on their own experiences: the rise of patient-reported outcomes in oncology drug trials..
60:2604-2605.
2019
-
Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis..
60:2384-2393.
2019
-
Clinicopathologic and genetic spectrum of infantile B-lymphoblastic leukemia: a multi-institutional study..
60:1006-1013.
2019
-
Fluoroquinolone prophylaxis reduces febrile neutropenia, bloodstream infections from mucosal translocations, and intensive care admissions in high risk hematological patients, a single center experience..
60:488-492.
2019
-
BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients..
60:234-237.
2019
-
Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey..
59:2723-2726.
2018
-
Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma..
58:1872-1879.
2017
-
Weight change trends and overall survival in United States veterans with follicular lymphoma treated with chemotherapy..
58:851-858.
2017
-
Immunophenotypic and diagnostic characterization of angioimmunoblastic T-cell lymphoma by advanced flow cytometric technology..
57:2804-2812.
2016
-
Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide..
57:2228-2231.
2016
-
An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia..
57:1800-1806.
2016
-
Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression..
57:1104-1113.
2016
-
Decreased normal NK-cells is a characteristic of T-cell large granular lymphocytic leukemia and is strongly associated with cytopenia..
57:1230-1233.
2016
-
(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study..
56:2005-2012.
2015
-
Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma..
56:1750-1755.
2015
-
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)..
56:958-964.
2015
-
Management of adverse events associated with idelalisib treatment: expert panel opinion..
56:2779-2786.
2015
-
A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course..
55:2114-2119.
2014
-
Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies..
55:1067-1075.
2014
-
CD38 variation as a prognostic factor in chronic lymphocytic leukemia..
55:191-194.
2014
-
Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma..
54:2627-2630.
2013
-
Stem cell factor expression in B cell malignancies is influenced by the niche..
54:2274-2280.
2013
-
The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)..
54:1405-1410.
2013
-
"Primum non nocere": the addition of granulocyte-macrophage colony stimulating factor to alemtuzumab in chronic lymphocytic leukemia..
54:441-442.
2013
-
Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma..
54:514-519.
2013
-
Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin..
54:284-289.
2013
-
Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome..
54:69-75.
2013
-
Chronic lymphocytic leukemia in African Americans..
53:2326-2329.
2012
-
Interim [(18)F]fluorodeoxyglucose positron emission tomography imaging in stage I-II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?.
53:2143-2150.
2012
-
Donor leukocyte infusions in recurrent Hodgkin lymphoma following allogeneic stem cell transplant: 10-year experience at the M. D. Anderson Cancer Center..
53:1239-1241.
2012
-
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant..
53:901-906.
2012
-
Molecular detection of circulating Sezary cells in patients with mycosis fungoides: could it predict future development of secondary Sezary syndrome? A single-institution experience..
53:868-877.
2012
-
Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia..
53:660-664.
2012
-
Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia..
53:435-440.
2012
-
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia..
53:218-224.
2012
-
Development of refractory anemia with ring sideroblasts associated with thrombocytosis from pre-existing refractory anemia with ring sideroblasts through acquisition of Jak2 V617F mutation..
52:2405-2407.
2011
-
Immunoglobulin class switch recombination in chronic lymphocytic leukemia..
52:1398-1400.
2011
-
Molecular evidence of a genotypically novel large T-cell lymphoma after anti-CD4 therapy for refractory mycosis fungoides..
52:905-907.
2011
-
A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254..
52:587-596.
2011
-
Statin use and need for therapy in chronic lymphocytic leukemia..
51:2295-2298.
2010
-
"Cannibalistic" phagocytosis in acute megakaryoblastic leukemia (AML M7) with t(10;17)(p15;q22)..
51:1944-1947.
2010
-
Monoclonal B cell lymphocytosis..
51:1386-1388.
2010
-
Primary testicular lymphoma: the site matters..
51:1159-1160.
2010
-
A sinusoidal large cell lymphoma with expression of CD30, CD15, and multiple B-cell antigens: a classical Hodgkin lymphoma with sinusoidal infiltrating pattern or a sinusoidal CD30 positive large B-cell lymphoma with CD15?.
51:1148-1151.
2010
-
Histiocytic sarcoma arising in indolent small B-cell lymphoma: report of two cases with molecular/genetic evidence suggestive of a 'transdifferentiation' during the clonal evolution..
51:802-812.
2010
-
Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901..
50:1589-1596.
2009
-
Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691..
50:1606-1617.
2009
-
[18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy..
50:904-911.
2009
-
Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival..
50:741-748.
2009
-
Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study..
49:2081-2090.
2008
-
Phase I evaluation of gemcitabine, mitoxantrone, and their effect on plasma disposition of fludarabine in patients with relapsed or refractory acute myeloid leukemia..
49:1523-1529.
2008
-
Pulmonary marginal zone lymphoma: a single centre experience and review of the SEER database..
49:1311-1320.
2008
-
High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin - a CALGB 59804 correlative study..
49:1202-1205.
2008
-
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells..
49:786-797.
2008
-
Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia..
49:543-553.
2008
-
Chemotherapy and the bone marrow stroma..
49:17-18.
2008
-
Changing patterns of chemotherapy relative dose intensity and supportive care for aggressive B-cell non-Hodgkin lymphoma.
2016